To the Editor: The most commonly used medications for patients with dementia are acetylcholinesterase inhibitors (AChEIs; donepezil, rivastigmine, galantamine). 1 Use of these medications are often limited by adverse events (AEs) including nausea, vomiting, diarrhea, incontinence, hypersalivation, sweating, lacrimation, rhinorrhea, and bronchorrhea. 1-3 In particular, rhinorrhea is not a well-recognized AE of AChEI and was only previously documented in a meta-analysis of randomized controlled trials of donepezil. 4 This AE may result in a prescribing cascade (PC) in which AChEI-induced rhinorrhea results in the use of a rhinorrhea medication rather than discontinuation or a dose reduction of AChEI. 5 The AChEI-induced rhinorrhea PC has not been described beyond a case report. 6 We aimed to assess this PC using a sample of patient visits from the United States.We used the 2014 and 2015 National Ambulatory Medical Care Survey (NAMCS) data that comprises medications from providers' notes including prescription and over-thecounter (OTC) products. Patient visits included those aged 55 years and older and treated with an antidementia medication (AChEI or memantine, an N-methyl-D-aspartate [NMDA] antagonist). We compared AChEI users (AChEI with or without memantine) with non-AChEI users (memantine only) because memantine is not associated with rhinorrhea. 7 We assessed the co-use of rhinorrhea medications (RMs; ie, medications used to treat rhinorrhea) that served as markers for a potential AChEI-induced rhinorrhea PC. RMs included firstgeneration histamine 1 (H 1 )-blockers, second-generation H 1 blockers, nasal anticholinergics, nasal glucocorticoids, and montelukast, a leukotriene antagonist (full list available on request). 8 We adjusted for age, sex, race, geographic region, year, comorbidities, and number of concomitant medications excluding RMs. 9 Data were analyzed using the sampling visit weights that were used to produce national estimates and account for survey clustering. We compared the percentage of visits in which RMs were used among AChEI users vs non-AChEI users. Weighted odds ratios (ORs) and 95% confidence intervals (CIs) were used to calculate univariate and multivariable analyses. We also estimated the percentage of patient visits impacted by the AChEI-induced rhinorrhea PC by subtracting the percentages of AChEI users from non-AChEI users who co-used RMs.There were an estimated 14 743 000 (95% CI = 11 493 000-17 993 000) patient visits in which a patient aged 55 years or older was taking an antidementia medication (using weighted estimates). Among antidementia medication user visits, 85.6% (n = 12 606 000) were taking an AChEI (with donepezil the most common [n = 10 813 000]). Memantine was used in